What is nonasthmatic eosinophilic bronchitis, and what are the recommended diagnostic steps and treatment options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nonasthmatic Eosinophilic Bronchitis: Definition, Diagnosis, and Treatment

What is NAEB?

Nonasthmatic eosinophilic bronchitis (NAEB) is a corticosteroid-responsive chronic cough condition characterized by eosinophilic airway inflammation WITHOUT the variable airflow obstruction or airway hyperresponsiveness that defines asthma 1. This condition accounts for 10-30% of chronic cough cases referred for specialist evaluation 2, 1.

Key Distinguishing Features

NAEB differs from asthma primarily in:

  • Normal spirometry with no evidence of airflow obstruction
  • Normal airway hyperresponsiveness (methacholine PC20 >16 mg/mL)
  • Presence of sputum eosinophilia (≥3% non-squamous cells)
  • Isolated chronic cough without wheeze or dyspnea 1

The pathophysiologic difference lies in mast cell localization: in NAEB, mast cells infiltrate the bronchial epithelium, whereas in asthma they infiltrate the airway smooth muscle, explaining why NAEB patients don't develop bronchospasm 1.


Diagnostic Algorithm

Step 1: Clinical Screening

Look for chronic cough (≥8 weeks duration) in a nonsmoker without:

  • Wheeze or dyspnea
  • Overt radiologic evidence of lung disease
  • Response to bronchodilators 1

Step 2: Exclude Other Causes

Perform:

  • Chest radiograph (must be normal)
  • Spirometry (must show normal lung function)
  • Methacholine challenge test (must be negative, PC20 >16 mg/mL) 1

Step 3: Confirm Eosinophilic Inflammation

The gold standard is induced sputum analysis showing ≥3% eosinophils 1.

Sputum induction protocol:

  • Pre-medicate with short-acting bronchodilator
  • Inhale hypertonic saline (3%, 4%, 5%) sequentially for 5 minutes each via ultrasonic nebulizer
  • Process same-day for cell count (requires specialized lab capability) 1

Alternative if sputum induction unavailable or unsuccessful:

  • Bronchial wash fluid at bronchoscopy provides similar information 1
  • Elevated fractional exhaled nitric oxide (FeNO) supports the diagnosis but is not diagnostic alone 1

Step 4: Confirm Diagnosis with Treatment Response

Diagnosis is confirmed by improvement in cough following corticosteroid therapy combined with documented eosinophilia 1.


Treatment Algorithm

First-Line Treatment: Inhaled Corticosteroids

Start inhaled corticosteroids (ICS) as first-choice treatment 2. The 2020 CHEST guideline gives this a Grade 2B recommendation.

Practical approach based on evidence:

  • Initial dose: Budesonide 400 μg twice daily (or equivalent ICS) 1
  • Duration: Treat for at least 2-4 months to minimize relapse 2, 3

Critical caveat: A randomized trial showed that 1-month treatment resulted in 41.9% relapse rate versus only 12% with 3-month treatment at 1-year follow-up 3. The 2-month group showed intermediate results (20% relapse). Therefore, treat for a minimum of 2 months, preferably 3-4 months, to reduce recurrence risk.

Second-Line Treatment: Step-Up Therapy

If response to ICS is incomplete after 2-4 weeks, escalate treatment 2:

  1. Increase ICS dose (e.g., double the dose)
  2. Add leukotriene receptor antagonist (e.g., montelukast) 2
  3. Reconsider alternative causes of cough before escalating further

Important note: The 2020 CHEST guideline rates this as Grade 2C (weak recommendation) due to limited trial data 2.

Third-Line Treatment: Oral Corticosteroids

For persistent or refractory cases:

  • Oral prednisone may be required, occasionally long-term 1
  • No specific dosing guidelines exist; use clinical judgment based on asthma treatment principles

Emerging Therapies

Anti-IL-5 biologics (e.g., mepolizumab, benralizumab) show promise for refractory NAEB, though evidence is limited 4. Consider in patients requiring chronic oral steroids or with frequent relapses.


Common Pitfalls and Caveats

Pitfall #1: Missing the diagnosis

  • NAEB is often misdiagnosed as asthma if patients receive empiric corticosteroids and improve, without objective testing for airflow obstruction or hyperresponsiveness 1
  • Always perform spirometry and methacholine challenge before labeling as asthma

Pitfall #2: Inadequate treatment duration

  • Stopping ICS too early (e.g., after 1 month) leads to high relapse rates 3
  • Treat for minimum 2-4 months initially

Pitfall #3: Multiple causes of cough

  • NAEB frequently coexists with other causes of chronic cough (post-nasal drip, GERD) 1
  • Consider NAEB even when another cause is identified if response to treatment is incomplete

Pitfall #4: Occupational/allergen exposure

  • Like asthma, NAEB can be triggered by occupational sensitizers or common allergens 2, 1
  • Always inquire about workplace exposures and consider avoidance strategies

Natural History and Prognosis

The condition can be:

  • Transient (self-limiting)
  • Episodic (recurrent)
  • Persistent (chronic without treatment) 1

While generally benign, some patients may develop:

  • Classic asthma (progression occurs in some cases) 2
  • Chronic airflow obstruction (rare) 5
  • Requirement for long-term oral corticosteroids 1

Response to treatment is generally excellent when eosinophilic inflammation is present and adequately treated 1, 5.

Related Questions

What is the recommended treatment for non‑asthmatic eosinophilic bronchitis?
In an adult aged 30‑60 years with a chronic dry cough lasting >8 weeks, normal spirometry, negative methacholine (or mannitol) challenge, and induced sputum eosinophil percentage ≥3% after excluding asthma, gastro‑oesophageal reflux disease, upper‑airway cough syndrome and smoking‑related disease, how should non‑asthmatic eosinophilic bronchitis be diagnosed and managed, including first‑line inhaled corticosteroid (e.g., budesonide or fluticasone propionate) dosing, second‑line leukotriene‑receptor antagonist (montelukast) or oral prednisone use, biologic therapy (mepolizumab) considerations, and criteria for tapering therapy?
Can a pulmonologist diagnose and manage a patient with cough possibly due to upper‑airway cough syndrome or non‑asthmatic eosinophilic bronchitis, given her positive response to oral and systemic steroids?
How should I manage a patient with cough, peripheral eosinophilia, and elevated immunoglobulin E (IgE)?
What is the role of Immunoglobulin E (IgE) and eosinophil count in managing chronic cough post viral infection?
What is the appropriate management of suspected isoniazid-induced hepatitis?
How should a patient with a corpus luteum cyst presenting with severe abdominal pain be managed?
What are the possible causes of nausea, vomiting sensation, vertigo, and sweating in a 76-year-old woman with no known comorbidities?
What are the non‑surgical treatment options for adenomyosis?
What does monosomy 7 (loss of one copy of chromosome 7) in 52% of cells indicate?
What does TTR (time in therapeutic range) refer to in anticoagulation management—is it a treatment chart?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.